Sirius Launches Phase 1 Trial for Innovative FXI siRNA Anticoagulant in Thromboembolic Treatment

Sirius Therapeutics, a biotech firm, has initiated a Phase 1 clinical trial for SRSD107, an innovative siRNA treatment aimed at preventing and managing thromboembolic disorders by targeting coagulation Factor XI (FXI). The trial, which began on January 30, 2024, in Australia, is the company's second foray into cardiovascular disease treatment after the SRSD101 trial for dyslipidemia in China.
Dr. Qunsheng Ji, CEO of Sirius Therapeutics, highlighted the drug's potential, citing preclinical studies that showed a significant reduction in FXI levels without causing bleeding, following a single subcutaneous administration. The clinical study will assess the safety, tolerability, and pharmacological profile of SRSD107 in healthy subjects through single and multiple dose regimens.
Thromboembolic disorders, which include conditions like heart attacks and strokes, are a leading cause of death globally, accounting for a quarter of all fatalities worldwide according to research published in The Lancet.
SRSD107 is a cutting-edge siRNA designed to specifically target and suppress the expression of FXI mRNA, thus impeding the coagulation cascade and offering an anticoagulant effect. The drug's design suggests it could be administered annually or semi-annually.
Sirius Therapeutics, established in 2021, is focused on developing advanced siRNA therapies for the global market, with a particular emphasis on cardiovascular diseases. The company's most advanced products are SRSD107 and SRSD101. With an innovative discovery center in the U.S. and a translational medicine center in China, Sirius has secured nearly $100 million in funding from a consortium of investors including OrbiMed, Creacion Ventures, Hankang Capital, Delos Capital, and its leadership team.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!